Navigation Links
OrthoAccel Technologies, Inc. Announces New Chief Financial Officer
Date:12/7/2011

HOUSTON, Dec. 7, 2011 /PRNewswire/ -- OrthoAccel Technologies, Inc., developers of the AcceleDent™ System, which is an acceleration device to enhance orthodontics, announced a new CFO, Andrew Layman, this week.  Mr. Layman began effective December 1, and will oversee all administrative and finance functions at OrthoAccel.

AcceleDent is a simple, removable and non-invasive appliance that a patient wears with braces or aligners in the mouth for 20 minutes daily to accelerate orthodontic tooth movement. The Company announced FDA clearance last month.  A randomized, controlled clinical trial conducted at the University of Texas Health Science Center at San Antonio demonstrated, with statistical significance, that tooth movement could be accelerated by 106% during the alignment phase and 38% to 50% during space closure.  There was no evidence of incremental root resorption or adverse events, thus demonstrating an excellent safety profile for the appliance.

Mr. Layman joins OrthoAccel as it prepares for its US market launch, amidst growing sales outside of the US.  He brings a diverse background that spans international finance, accounting, audit, and tax experience.  Mr. Layman is a CPA, and previously spent eight years at a "Big Four" public accounting firm.  His operating experience is broad, ranging from start-up to financial responsibility for a $3 billion division at Flextronics International, a leading electronics manufacturing services provider to the world's top technology brands.

Michael Lowe, CEO of OrthoAccel, commented, "We knew that 2012 would involve managing significant growth, and that it would be important to bring in an experienced finance executive."    Product availability to US doctors is scheduled for January 2012.  "We could not be more pleased with where the process led us.  Andy is a perfect fit in every way.  His track record for establishing risk management and internal controls will be an important part of our growth," Lowe continued. 

Mr. Layman remarked, "I am very pleased to join the management team at OrthoAccel during this exciting, rapid growth time."

Last month, in addition to FDA clearance, the Company announced a major partnership with a distributor in the Italy market.  Plans related to additional clinical trial activity with key university partners, both inside and outside of the US, are scheduled to be announced in the first quarter of 2012.

About OrthoAccel® Technologies, Inc.
Based in Houston, Texas, OrthoAccel® Technologies, Inc. is a privately owned medical device company currently engaged in the development, manufacturing, and marketing of products to enhance dental care and orthodontic treatment. OrthoAccel currently sells its products in ten markets world-wide and received FDA clearance in November 2011 for the AcceleDent™ System. Product availability for US doctors is scheduled for January 2012.

About the AcceleDent™ System
AcceleDent™
represents the first clinical approach to accelerate orthodontic tooth movement via modulating bone biology. The appliance has been studied clinically as a complement to conventional fixed orthodontic appliances to apply gentle pulsing forces to the dentition to move teeth faster through accelerated bone remodeling. More information can be found at www.acceledent.com and www.acceledent.co.uk or requested via info@orthoaccel.com.


'/>"/>
SOURCE OrthoAccel Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. OrthoAccel Technologies, Inc. and AB Orthodontics Announce Partnership and Australian Product Introduction
2. OrthoAccel Technologies, Inc. Announces Definitive Distribution Agreements in Two Key Markets
3. OrthoAccel Technologies Announces Full-Market Release of AcceleDent, a New Technology to Shorten Treatment Time in Braces
4. OrthoAccel Technologies Committed to Plans for Positioning the United Kingdom as a Key Strategic Market for New Orthodontic Technology
5. Medical Device Industry Executive Joins OrthoAccel Technologies, Inc. Board of Directors
6. OrthoAccel Technologies, Inc. Announces New Scientific Advisor
7. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
8. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
9. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
10. Palatin Technologies, Inc. Reports Initiation of Human Trials for the Treatment of Congestive Heart Failure
11. Emisphere Technologies, Inc. Announces 2007 Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
(Date:6/23/2016)... , June 23, 2016 Research and ... News Issue 52" report to their offering. ... influenza treatment creates a favourable commercial environment for MedImmune to ... patient base that will serve to drive considerable growth for ... would serve to cap sales considerably, but development is still ...
(Date:6/23/2016)... Revolutionary technology includes multi-speaker listening to conquer ... in advanced audiology and hearing aid technology, has today ... world,s first internet connected hearing aid that opens up ...      (Photo: http://photos.prnewswire.com/prnh/20160622/382240 ) , ... , TwinLink™ - the first dual communication ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture ... said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package ... Final Cut Pro X . Simply select a ProHand generator and drag it ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has dedicated ... has implemented orthobiologic procedures as a method for treating his patients. The procedure ... doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to ...
(Date:6/24/2016)... ... ... A recent article published June 14 on E Online details ... to state that individuals are now more comfortable seeking to undergo not only the ... and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) notes ...
(Date:6/24/2016)... ... 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out of ... verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... throw rocks at my other children and say he was going to kill them. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be ...
Breaking Medicine News(10 mins):